295 related articles for article (PubMed ID: 28697759)
1. The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model.
Hsu YC; Chiu YC; Lin CC; Kuo YY; Hou HA; Tzeng YS; Kao CJ; Chuang PH; Tseng MH; Hsiao TH; Chou WC; Tien HF
J Hematol Oncol; 2017 Jul; 10(1):139. PubMed ID: 28697759
[TBL] [Abstract][Full Text] [Related]
2. Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation.
Nagase R; Inoue D; Pastore A; Fujino T; Hou HA; Yamasaki N; Goyama S; Saika M; Kanai A; Sera Y; Horikawa S; Ota Y; Asada S; Hayashi Y; Kawabata KC; Takeda R; Tien HF; Honda H; Abdel-Wahab O; Kitamura T
J Exp Med; 2018 Jun; 215(6):1729-1747. PubMed ID: 29643185
[No Abstract] [Full Text] [Related]
3. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.
Abdel-Wahab O; Gao J; Adli M; Dey A; Trimarchi T; Chung YR; Kuscu C; Hricik T; Ndiaye-Lobry D; Lafave LM; Koche R; Shih AH; Guryanova OA; Kim E; Li S; Pandey S; Shin JY; Telis L; Liu J; Bhatt PK; Monette S; Zhao X; Mason CE; Park CY; Bernstein BE; Aifantis I; Levine RL
J Exp Med; 2013 Nov; 210(12):2641-59. PubMed ID: 24218140
[TBL] [Abstract][Full Text] [Related]
4. HHEX promotes myeloid transformation in cooperation with mutant ASXL1.
Takeda R; Asada S; Park SJ; Yokoyama A; Becker HJ; Kanai A; Visconte V; Hershberger C; Hayashi Y; Yonezawa T; Tamura M; Fukushima T; Tanaka Y; Fukuyama T; Matsumoto A; Yamasaki S; Nakai K; Yamazaki S; Inaba T; Shibata T; Inoue D; Honda H; Goyama S; Maciejewski JP; Kitamura T
Blood; 2020 Oct; 136(14):1670-1684. PubMed ID: 32492700
[TBL] [Abstract][Full Text] [Related]
5. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
Bera R; Chiu MC; Huang YJ; Lin TH; Kuo MC; Shih LY
J Hematol Oncol; 2019 Oct; 12(1):104. PubMed ID: 31640815
[TBL] [Abstract][Full Text] [Related]
6. Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia.
Fisher CL; Pineault N; Brookes C; Helgason CD; Ohta H; Bodner C; Hess JL; Humphries RK; Brock HW
Blood; 2010 Jan; 115(1):38-46. PubMed ID: 19861679
[TBL] [Abstract][Full Text] [Related]
7. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
Asada S; Kitamura T
Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
[TBL] [Abstract][Full Text] [Related]
8. Modeling ASXL1 mutation revealed impaired hematopoiesis caused by derepression of p16Ink4a through aberrant PRC1-mediated histone modification.
Uni M; Masamoto Y; Sato T; Kamikubo Y; Arai S; Hara E; Kurokawa M
Leukemia; 2019 Jan; 33(1):191-204. PubMed ID: 29967380
[TBL] [Abstract][Full Text] [Related]
9. Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice.
Wang J; Li Z; He Y; Pan F; Chen S; Rhodes S; Nguyen L; Yuan J; Jiang L; Yang X; Weeks O; Liu Z; Zhou J; Ni H; Cai CL; Xu M; Yang FC
Blood; 2014 Jan; 123(4):541-53. PubMed ID: 24255920
[TBL] [Abstract][Full Text] [Related]
10. [Role of ASXL1 mutations in hematological disorders].
Uni M
Rinsho Ketsueki; 2019; 60(6):680-690. PubMed ID: 31281161
[TBL] [Abstract][Full Text] [Related]
11. The ASXL1-G643W variant accelerates the development of CEBPA mutant acute myeloid leukemia.
D'Altri T; Wilhelmson AS; Schuster MB; Wenzel A; Kalvisa A; Pundhir S; Meldgaard Hansen A; Porse BT
Haematologica; 2021 Apr; 106(4):1000-1007. PubMed ID: 32381577
[TBL] [Abstract][Full Text] [Related]
12. The role of ASXL1 in hematopoiesis and myeloid malignancies.
Asada S; Fujino T; Goyama S; Kitamura T
Cell Mol Life Sci; 2019 Jul; 76(13):2511-2523. PubMed ID: 30927018
[TBL] [Abstract][Full Text] [Related]
13. [Role of ASXL1 mutation in myeloid malignancies].
Sheng MY; Zhou Y; Xu MJ; Yang FC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1183-7. PubMed ID: 25130853
[TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.
Inoue D; Kitaura J; Togami K; Nishimura K; Enomoto Y; Uchida T; Kagiyama Y; Kawabata KC; Nakahara F; Izawa K; Oki T; Maehara A; Isobe M; Tsuchiya A; Harada Y; Harada H; Ochiya T; Aburatani H; Kimura H; Thol F; Heuser M; Levine RL; Abdel-Wahab O; Kitamura T
J Clin Invest; 2013 Nov; 123(11):4627-40. PubMed ID: 24216483
[TBL] [Abstract][Full Text] [Related]
15. Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway.
Fujino T; Goyama S; Sugiura Y; Inoue D; Asada S; Yamasaki S; Matsumoto A; Yamaguchi K; Isobe Y; Tsuchiya A; Shikata S; Sato N; Morinaga H; Fukuyama T; Tanaka Y; Fukushima T; Takeda R; Yamamoto K; Honda H; Nishimura EK; Furukawa Y; Shibata T; Abdel-Wahab O; Suematsu M; Kitamura T
Nat Commun; 2021 Mar; 12(1):1826. PubMed ID: 33758188
[TBL] [Abstract][Full Text] [Related]
16. Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies.
Yang H; Kurtenbach S; Guo Y; Lohse I; Durante MA; Li J; Li Z; Al-Ali H; Li L; Chen Z; Field MG; Zhang P; Chen S; Yamamoto S; Li Z; Zhou Y; Nimer SD; Harbour JW; Wahlestedt C; Xu M; Yang FC
Blood; 2018 Jan; 131(3):328-341. PubMed ID: 29113963
[TBL] [Abstract][Full Text] [Related]
17. Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9.
Kawagoe H; Grosveld GC
Blood; 2005 Dec; 106(13):4269-77. PubMed ID: 16105979
[TBL] [Abstract][Full Text] [Related]
18. Role of ASXL1 in hematopoiesis and myeloid diseases.
Gao X; You X; Droin N; Banaszak LG; Churpek J; Padron E; Geissler K; Solary E; Patnaik MM; Zhang J
Exp Hematol; 2022 Nov; 115():14-19. PubMed ID: 36183966
[TBL] [Abstract][Full Text] [Related]
19. Knock-out of Hopx disrupts stemness and quiescence of hematopoietic stem cells in mice.
Lin CC; Yao CY; Hsu YC; Hou HA; Yuan CT; Li YH; Kao CJ; Chuang PH; Chiu YC; Chen Y; Chou WC; Tien HF
Oncogene; 2020 Jul; 39(28):5112-5123. PubMed ID: 32533098
[TBL] [Abstract][Full Text] [Related]
20. Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors.
Braun TP; Estabrook J; Schonrock Z; Curtiss BM; Darmusey L; Macaraeg J; Enright T; Coblentz C; Callahan R; Yashar W; Taherinasab A; Mohammed H; Coleman DJ; Druker BJ; Demir E; Lusardi TA; Maxson JE
Leukemia; 2023 Feb; 37(2):478-487. PubMed ID: 36526735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
